hepatitis C

See the following -

A Law Professor’s Big Idea for Combating Greedy Drug Company Titans Like Martin Shkreli

Noah Berlatsky | Quartz | September 21, 2017

In 2015, CEO of Turing Pharmaceuticals Martin Shkreli infamously raised the price of the life-saving drug Daraprim by 5,000%. Daraprim, developed more than 60 years ago, is used to treat the deadly parasitic infection toxoplasmosis. It was selling for $13.50 a pill; then Turing raised the price to $750. The move sparked massive backlash and Congressional hearings, and Shkreli himself was eventually arrested for, and convicted of, unrelated securities fraud charges. But the original, horrible problem didn’t get fixed. Turing kept the price sky-high; as of August 2016, many patients were paying $375 per pill...

Read More »

Conshohocken-Based Non-Profit Aims to Revolutionize Biopharma

T. J. Sharpe | Philly.com | December 1, 2016

What if the next big thing in biopharma wasn’t produced by one of the big pharma companies that line the Northeast corridor between Philadelphia and New York City, but by a whole bunch of them?  Conshohocken-based TransCelerate BioPharma is attempting to accomplish this difficult feat by embracing cooperation instead of competition.  It is a 501(c)3 non-profit consortium of 18 pharmaceutical companies (and growing) that works with the FDA and global regulators to advance the industry through collaboration with researchers, industry organizations, and federal oversight agencies...

Read More »

Cyber-Attacks on Healthcare Institutions on the Rise: Public Health Watch Report

Brian P. Dunleavy | Contagion Live | August 2, 2017

With news this week that White House officials were fooled by a self-proclaimed “email prankster”—who posed as Jared Kushner, President Donald Trump’s advisor and son-in-law, and recently ousted Chief of Staff, Reince Priebus, during correspondences with various cabinet members—it’s worth remembering that there are cybersecurity implications for healthcare institutions as well...

Read More »

Healthcare Big Data Silos Prevent Delivery of Coordinated Care

Brent Clough | Health IT Analytics | August 19, 2016

Complaints about silos in healthcare are nothing new. For a patient to fill a single prescription, there are several disconnected groups that need to work together to move the process forward. The specialist and the primary doctor have to connect and share information, and the payer and provider need to be on the same page. Unfortunately, for patients across the country, these stakeholders are moving at different speeds and in different directions, preventing true collaboration across organizations...

Read More »

Hepatitis C Drug Costing VA, DoD Millions

Patricia Kime | Military Times | January 7, 2015

One of the costliest drugs on the market threatens the Veterans Affairs Department's health budget — to the point that VA, which added the medication to its formulary in April, provides it to only the sickest patients who need it...

Read More »

IBM And University Scientists Launch Global Computing Effort To Find Cures For Dengue, West Nile, And Hepatitis C Diseases

Press Release | International Business Machines Corporation (IBM), University of Texas Medical Branch (UTMB) | August 23, 2007

Researchers Say the 50,000 Years of Computer Time Needed to Discover Cures May Be Achieved in One Year Using World Community Grid Read More »

Let's Pay For Open Source With A Closed-Source Software Levy

Glyn Moody | ComputerWorld UK | October 22, 2014

This column has often explored ways in which some of the key ideas underlying free software and open source are being applied in other fields. But that equivalence can flow in both directions: developments in fields outside the digital world may well have useful lessons for computing...

Read More »

Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power

Matt Krantz | USA Today | August 25, 2016

Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...

Read More »

On the Lack of Good Medical Evidence for the New $100,000 Hepatitis C Drug Treatments

As we wrote, most recently last week, the hepatitis C screening and treatment bandwagon keeps rolling along.  There is constant public argument whether about the prices of treatment regimens, which approach $100,000 per patient in the US...However, starting in March, 2014, we have posted about the lack of good evidence from clinical research suggesting these drugs are in fact so wondrous...

Read More »

Startup Emocha's App To Help Baltimore Patients Manage Tuberculosis

Sarah Gantz | Baltimore Business Journal | October 27, 2014

Baltimore health IT startup Emocha Mobile Health Inc. is partnering with Baltimore City to test out its medication adherence application with tuberculosis patients...

Read More »

Telehealth Progress Requires Beefed Up Network Infrastructure

Rutrell Yasin | Federal Times | January 23, 2015

Federal agencies have applied telehealth technology in innovative ways to expand health care beyond the walls of veterans' hospitals and other care facilities. Current efforts allow caregivers to reach patients in their daily lives while clinicians and specialists can share and archive medical information...

Read More »

‘Superbug’ Scourge Spreads as U.S. Fails to Track Rising Human Toll

Ryan McNeill, Deborah J. Nelson and Yasmeen Abutaleb | Reuters | September 7, 2016

Fifteen years after the U.S. declared drug-resistant infections to be a grave threat, the crisis is only worsening, a Reuters investigation finds, as government agencies remain unwilling or unable to impose reporting requirements on a healthcare industry that often hides the problem...

Read More »